# An Imaging Study of [18]F-fluoro-3'-Deoxy-3'-L-fluorothymidine ([18]F-FLT) in Patients With Locally Advanced or Metastatic Pancreatic Cancer Who Will be Treated With Gemcitabine or Other Nucleoside Analogs

> **NCT00414570** · EARLY_PHASE1 · TERMINATED · sponsor: **AHS Cancer Control Alberta** · enrollment: 11 (actual)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** [18]F-FLT PET scan

## Key facts

- **NCT ID:** NCT00414570
- **Lead sponsor:** AHS Cancer Control Alberta
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-11
- **Primary completion:** 2019-02-06
- **Final completion:** 2019-02-06
- **Target enrollment:** 11 (ACTUAL)
- **Why stopped:** Retirement of former Qualified Investigator and lack of resources to complete study
- **Last updated:** 2019-08-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00414570

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00414570, "An Imaging Study of [18]F-fluoro-3'-Deoxy-3'-L-fluorothymidine ([18]F-FLT) in Patients With Locally Advanced or Metastatic Pancreatic Cancer Who Will be Treated With Gemcitabine or Other Nucleoside Analogs". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00414570. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*